Article Text
Statistics from Altmetric.com
‘The people of this country have had enough of experts…’
This extraordinary quotation is from a British politician who most definitely is not a neurologist, and certainly not a reader of Practical Neurology. Readers of this journal love experts, and particularly those who think critically about what they do, and can distil their knowledge so that we, the jobbing neurologists, can make this expertise available to our patients. Experts are sometimes characterised (unfairly) as knowing a lot about a little, about those rare diseases that we rarely see in the clinic.
Dementia is very common and all too often the diagnosis is relatively straightforward, particularly for more established disease. But having made the diagnosis what should we do next? Tony Bayer shares his expertise in the management of patients with dementia and highlights a range of simple and low-tech interventions that can help both the patient with dementia and their family (page 296).
Stroke …
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell - related adverse events
- Study protocol for THINK: a multinational open - label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
- Emerging immunotherapies in multiple myeloma
- Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
- Treatment of patients with relapsed or refractory CD19 + lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD 28.4-1BBzeta retroviral vector: a unicentre phase I / II clinical trial protocol
- Modulating TNFα activity allows transgenic IL15 - Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
- The Great Debate at ‘ Immunotherapy Bridge ’, Naples, December 5, 2019